US Edition
Atraverse closes US$29 million to boost commercialisation of Hotwire transseptal access technology - Cardiovascular News
Summary by Cardiovascular News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Atraverse closes US$29 million to boost commercialisation of Hotwire transseptal access technology - Cardiovascular News
Atraverse Medical has announced the close of US$29.4 million in follow-on financing to accelerate growth, building upon the US$12.5 million in prior seed investment that was previously used to obtain US Food and Drug Administration (FDA) 510(k) clearance and begin early commercialisation of Hotwire—the company’s novel radiofrequency (RF) guidewire for left-heart access. Designed to simplify left-heart access through universal sheath compatibilit…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
